Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBT (2019 - 2025)

Historic EBT for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$8.7 million.

  • Keros Therapeutics' EBT rose 8356.37% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year increase of 13788.76%. This contributed to the annual value of -$187.1 million for FY2024, which is 2226.33% down from last year.
  • As of Q3 2025, Keros Therapeutics' EBT stood at -$8.7 million, which was up 8356.37% from -$32.9 million recorded in Q2 2025.
  • Keros Therapeutics' EBT's 5-year high stood at $158.5 million during Q1 2025, with a 5-year trough of -$53.0 million in Q3 2024.
  • For the 5-year period, Keros Therapeutics' EBT averaged around -$21.1 million, with its median value being -$29.7 million (2022).
  • Per our database at Business Quant, Keros Therapeutics' EBT crashed by 50145.72% in 2022 and then soared by 46761.61% in 2025.
  • Quarter analysis of 5 years shows Keros Therapeutics' EBT stood at -$4.9 million in 2021, then plummeted by 501.46% to -$29.7 million in 2022, then plummeted by 56.32% to -$46.5 million in 2023, then grew by 1.57% to -$45.7 million in 2024, then surged by 80.96% to -$8.7 million in 2025.
  • Its EBT was -$8.7 million in Q3 2025, compared to -$32.9 million in Q2 2025 and $158.5 million in Q1 2025.